ReviewCurrent heart failure reports2016
Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.
Review in Current heart failure reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Association of the pan-immune-inflammation value with 60-day in-hospital mortality in critically ill patients with acute myocardial infarction: evidence from the MIMIC-IV database.BMC cardiovascular disorders · 2026Article
- Predictors of Left Ventricular Reverse Remodeling in Heart Failure with Reduced Ejection Fraction.Current heart failure reports · 2025Review
- Myocardial Recovery and Relapse in Heart Failure With Improved Ejection Fraction.Current treatment options in cardiovascular medicine · 2024Article
- Role of Imaging and Biomarkers in Identifying, Monitoring, and Promoting Myocardial Recovery.Methodist DeBakey cardiovascular journal · 2024Review
- Myocardial Recovery.Diagnostics (Basel, Switzerland) · 2023Review
- A review of biomarker and imaging monitoring to predict heart failure recovery.Frontiers in cardiovascular medicine · 2023Review
- Pediatric and adult dilated cardiomyopathy are distinguished by distinct biomarker profiles.Pediatric research · 2022Article
- Procollagen C-proteinase enhancer-1 (PCPE-1), a potential biomarker and therapeutic target for fibrosis.Matrix biology plus · 2021Article
- Surgical and physiological challenges in the development of left and right heart failure in rat models.Heart failure reviews · 2019Review
- The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.Journal of cardiovascular translational research · 2018 · on this mapArticle
- Paeoniflorin improves cardiac function and decreases adverse postinfarction left ventricular remodeling in a rat model of acute myocardial infarction.Drug design, development and therapy · 2018Article
- The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update.JACC. Cardiovascular imaging · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular remodeling appears to be a critical link between cardiac injury and the development and progression of heart failure with reduced ejection fraction (HFrEF). Several drug and device therapies that modify and reverse the remodeling process in patients with HFrEF are closely associated with improvement in clinical outcomes. Reverse remodeling, including partial or complete recovery of systolic function and structure, is possible but its determinants are incompletely understood. Methods to predict reverse remodeling in response to therapy are not well defined. Though non-invasive imaging techniques remain the most widely used methods of assessing reverse remodeling, serum biomarkers are now being investigated as more specific, mechanistically driven, and clinically useful predictors of reverse remodeling. Biomarkers that reflect myocyte stretch and stress, myocyte injury and necrosis, inflammation and fibrosis, and extracellular matrix turnover may be particularly valuable for predicting pathophysiologic changes and prognosis in individual patients. Their use may ultimately allow improved application of precision medicine in chronic HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.